ethyl (Z)-2-fluoro-4-methylhex-2-enoate | 1012043-70-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (Z)-2-fluoro-4-methylhex-2-enoate
• CAS: 1012043-70-7
• 化学式: C₉H₁₅FO₂
• 分子量: 174.215
• InChiKey: RKRXCDYDSDJHII-VURMDHGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基丁醛 、 二溴氟乙酸乙酯 在 锰 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以62%的产率得到ethyl (Z)-2-fluoro-4-methylhex-2-enoate
  参考文献：
  名称：

  Stereoselective synthesis of (Z)-α-halo-α,β-unsaturated esters, and amides from aldehydes and trihaloesters or amides promoted by manganese

  摘要：

  描述了一种锰促进的连续过程的初步结果，该过程旨在立体选择性合成不同的(Z)-α-卤代-α,β-不饱和化合物。

  DOI：

  10.1039/b717513b

文献信息

• Stereoselective Olefination Reactions Promoted by Rieke Manganese
  作者：José Concellón、Humberto Rodríguez-Solla、Vicente del Amo、Pamela Díaz

  DOI：10.1055/s-0029-1216880

  日期：2009.8

  applied to develop a novel and direct synthesis of (E)-α,β-unsaturated esters or amides and (Z)-α,β-unsaturated α-halo esters and α-choroamides through a Mn*-mediated sequential olefination protocol of aldehydes with dichloro esters or amides and trihalo esters or trichloroamides, respectively. manganese - elimination reactions - stereoselectivity - α,β-unsaturated esters - α,β-unsaturated amides - metalation

  提出了使用廉价的无毒金属锰进行立体选择性β-消除反应并促进醛的顺序烯化反应以获得α，β-不饱和酯和酰胺的优势的研究。使用活性锰（Mn *）作为金属化剂进行了各种消除反应，所有这些反应均具有完全的立体选择性和高收率的特征。锰的这种能力已被用于开发通过Mn *-直接合成（E）-α，β-不饱和酯或酰胺与（Z）-α，β-不饱和α-卤代酯和α-氯酰胺的新颖而直接的合成方法。介导的醛分别与二氯酯或酰胺和三卤代酯或三氯酰胺的顺序烯烃化方案。 锰-消除反应-立体选择性-α，β-不饱和酯-α，β-不饱和酰胺-金属化
• Stereoselective synthesis of (Z)-α-haloacrylic acid derivatives, and (Z)-haloallylic alcohols from aldehydes and trihaloesters or amides promoted by Rieke manganese
  作者：José M. Concellón、Humberto Rodríguez-Solla、Pamela Díaz

  DOI：10.1039/b803449d

  日期：——

  A Mn*-promoted sequential process directed toward the synthesis of (Z)-α-halo-α,β-unsaturated esters or amides is described. In both cases, the process takes place with complete Z-stereoselectivity. In addition, (Z)-α-chloro-α,β-unsaturated ketones and carboxylic acids, and (Z)-haloallylic alcohols were readily prepared from (Z)-α-halo-α,β-unsaturated amides derived from morpholine, or esters. A mechanism has been proposed to explain the sequential process and the stereoselectivity observed.

  描述了一种Mn*-促进的顺序反应过程，旨在合成(Z)-α-卤代-α,β-不饱和酯或酰胺。在这两种情况下，该过程均具有完全的Z立体选择性。此外，从源自吗啉的(Z)-α-卤代-α,β-不饱和酰胺或酯中，能够容易地制备(Z)-α-氯代-α,β-不饱和酮、羧酸和(Z)-卤代烯醇。提出了一种机制来解释观察到的顺序过程和立体选择性。
• 2'-FLUORONUCLEOSIDES
  申请人：Schinazi Raymond F.

  公开号：US20080300398A1

  公开（公告）日：2008-12-04

  A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R 1 is OH, H, OR 3 , N 3 , CN, halogen, including F, or CF 3 , lower alkyl, amino, lower alkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base; R 2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R 2 is H or phosphate; sulfonate ester including alkyl or aryalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and R 3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

  本发明公开了一类2'-氟核苷化合物，可用于治疗乙型肝炎感染、丙型肝炎感染、HIV和异常细胞增殖，包括肿瘤和癌症。这些化合物具有以下通式： 其中，Base是嘌呤或嘧啶碱基；R1是OH、H、OR3、N3、CN、卤素（包括F）或CF3、低烷基、氨基、低烷基氨基、二（低）烷基氨基、或烷氧基，Base指的是嘌呤或嘧啶碱基；R2是H、磷酸酯（包括单磷酸酯、二磷酸酯、三磷酸酯或稳定的磷酸酯前药）、酰基或其他在体内可提供R2为H或磷酸酯的药学上可接受的离去基；磺酸酯，包括烷基或芳基磺酰基，包括甲烷磺酰基、苄基，其中苯基基团可选择地用上述给出的一个或多个取代基取代，脂质、氨基酸、肽或胆固醇；以及R3是酰基、烷基、磷酸酯或其他在体内可裂解为母化合物的药学上可接受的离去基，或其药学上可接受的盐。
• 2-Fluoronucleosides
  申请人：Schinazi Raymond F.

  公开号：US20100173863A1

  公开（公告）日：2010-07-08

  2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R 1 is OH, H, OR 3 , N 3 , CN, halogen, CF 3 , lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R 2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R 3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.

  披露了2'-氟核苷类化合物，可用于治疗乙型肝炎感染、丙型肝炎感染、HIV和异常细胞增殖，包括肿瘤和癌症。该化合物具有以下通式： 其中，Base是嘌呤或嘧啶碱基；R1是OH、H、OR3、N3、CN、卤素、CF3、低烷基、氨基、低烷基氨基、二（低）烷基氨基或烷氧基；R2是H、磷酸酯或稳定的磷酸酯前药、酰基或其他药学上可接受的离去基，如苯甲酰基、脂质、氨基酸、肽或胆固醇；R3是酰基、烷基、磷酸酯或其他药学上可接受的离去基；或其药学上可接受的盐。
• US7307065B2
  申请人：——

  公开号：US7307065B2

  公开（公告）日：2007-12-11